Myrexis Inc., of Salt Lake City, started a Phase IIb trial of Azixa (verubulin), a small molecule designed to act as a microtubule destabilizing agent, in front-line glioblastoma multiforme. The study will enroll up to 120 newly diagnosed patients and test Azixa plus standard of care vs. standard of care alone.